Enzyme-activated anticancer drugs, where a specific enzyme SULT1A1 converts a class of compounds into anticancer agents, have demonstrated the ability to kill liver cancer cells in cell and mouse models, potentially representing a new direction for future liver cancer treatment (52). Here, SULT1A1 is linked to liver cancer.